Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue$219.06M$219.06M+32.4% vs Q2 2025 Net Income-$58.37M-$58.37MN/M vs Q2 2025 EPS Diluted-$1.01-$1.01N/M vs Q2 2025 Operating Income-$57,963,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,378,000N/M Margins · derivedOperating margin-26.5%−33.8 pt vs Q2 2025
Net margin-26.6%−40.2 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 3, 2026 · 34 d after period end